Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Wassim Abida, Andrew W. Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R. Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R. Junttila, Pratik S. Multani, Anneleen DaemenEdna Chow Maneval, Christopher J. Logothetis, Michael J. Morris

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide'. Together they form a unique fingerprint.

Medicine & Life Sciences